

# Kanwal P S Raghav

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7808646/publications.pdf>

Version: 2024-02-01

65  
papers

2,937  
citations

236925

25  
h-index

182427

51  
g-index

66  
all docs

66  
docs citations

66  
times ranked

5071  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. <i>JAMA Oncology</i> , 2019, 5, e191870.  | 7.1  | 348       |
| 2  | Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2019, 5, 824.  | 7.1  | 335       |
| 3  | Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.                    | 7.0  | 225       |
| 4  | Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2033-2041.  | 7.0  | 224       |
| 5  | ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.  | 27.6 | 218       |
| 6  | Clinical and molecular characterization of earlyâ€“onset colorectal cancer. <i>Cancer</i> , 2019, 125, 2002-2010.   | 4.1  | 212       |
| 7  | CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. <i>EBioMedicine</i> , 2020, 61, 103030.   | 6.1  | 67        |
| 8  | Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0173345.   | 2.5  | 65        |
| 9  | Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UIMP): Prognostic Factors and Implications for Treatment and Follow-up. <i>Annals of Surgical Oncology</i> , 2017, 24, 187-193.                | 1.5  | 62        |
| 10 | Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa034.                             | 2.9  | 59        |
| 11 | Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. <i>Clinical Cancer Research</i> , 2019, 25, 6107-6118.   | 7.0  | 54        |
| 12 | MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. <i>Oncotarget</i> , 2016, 7, 54627-54631.  | 1.8  | 53        |
| 13 | Molecular Landscape of <i>ERBB2/ERBB3</i> Mutated Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1409-1417.  | 6.3  | 53        |
| 14 | Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.                          | 7.0  | 50        |
| 15 | Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of Vater: A singleâ€“center, openâ€“label, phase 2 study. <i>Cancer</i> , 2017, 123, 1011-1017. | 4.1  | 45        |
| 16 | Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1135-1141.  | 4.9  | 45        |
| 17 | Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas. <i>Oncologist</i> , 2013, 18, 1270-1277.   | 3.7  | 41        |
| 18 | Modeling of Patient-Derived Xenografts in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1435-1442.  | 4.1  | 40        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 54-61.   | 0.6 | 37        |
| 20 | Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. <i>Cancer Discovery</i> , 2021, 11, 2738-2747.                            | 9.4 | 37        |
| 21 | Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. <i>Clinical Colorectal Cancer</i> , 2018, 17, e699-e709.      | 2.3 | 34        |
| 22 | Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. <i>Cancer Medicine</i> , 2016, 5, 239-247.  | 2.8 | 33        |
| 23 | Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , 2017, 24, 4051-4058.                      | 1.5 | 32        |
| 24 | Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , 2019, 121, 505-510.  | 6.4 | 32        |
| 25 | Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup> -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.  | 3.0 | 31        |
| 26 | International Harmonization of Provisional Diagnostic Criteria for <i>ERBB2</i> -Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. <i>JCO Precision Oncology</i> , 2020, 4, 6-19. | 3.0 | 29        |
| 27 | Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .   | 6.3 | 28        |
| 28 | Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.  | 7.0 | 28        |
| 29 | Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives. <i>Current Oncology</i> , 2021, 28, 671-677.  | 2.2 | 27        |
| 30 | Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 199-212.   | 1.4 | 26        |
| 31 | The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. <i>Journal of the National Cancer Institute</i> , 2018, 110, 888-894.                                   | 6.3 | 26        |
| 32 | Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0183949.   | 2.5 | 25        |
| 33 | Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. <i>Clinical Cancer Research</i> , 2021, 27, 3414-3421.  | 7.0 | 25        |
| 34 | Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. <i>Cancer Medicine</i> , 2018, 7, 4880-4892.  | 2.8 | 23        |
| 35 | Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. <i>PLoS ONE</i> , 2016, 11, e0154985.   | 2.5 | 22        |
| 36 | Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 57-69.                                | 3.7 | 21        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Natural history and prognostic factors for localised small bowel adenocarcinoma. <i>ESMO Open</i> , 2020, 5, e000960.   | 4.5 | 20        |
| 38 | Untying the gordion knot of targeting MET in cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 95-103.  | 7.7 | 18        |
| 39 | Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. <i>British Journal of Cancer</i> , 2020, 123, 1262-1270.       | 6.4 | 18        |
| 40 | Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 37721-37732.                                    | 1.8 | 16        |
| 41 | Underreporting of Research Biopsies from Clinical Trials in Oncology. <i>Clinical Cancer Research</i> , 2017, 23, 6450-6457.  | 7.0 | 15        |
| 42 | Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. <i>BMC Cancer</i> , 2019, 19, 965.  | 2.6 | 12        |
| 43 | Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. <i>BMC Cancer</i> , 2017, 17, 331.   | 2.6 | 11        |
| 44 | Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018, 124, 2299-2305.   | 4.1 | 11        |
| 45 | Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. <i>JAMA Oncology</i> , 2019, 5, 402.          | 7.1 | 11        |
| 46 | Malignant Mesothelioma of the Peritoneum in Women. <i>American Journal of Surgical Pathology</i> , 2021, 45, 45-58.   | 3.7 | 11        |
| 47 | Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. <i>JAMA Network Open</i> , 2021, 4, e2119934.  | 5.9 | 11        |
| 48 | HepatoScoreâ€4: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. <i>Hepatology</i> , 2021, 73, 2278-2292.   | 7.3 | 10        |
| 49 | Modified gemcitabine plus nabâ€paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 5406-5415.   | 2.8 | 9         |
| 50 | Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 21193-21207.                                       | 1.8 | 9         |
| 51 | Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. <i>Oncologist</i> , 2020, 25, e1807-e1811.           | 3.7 | 7         |
| 52 | Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. <i>Cancer</i> , 2022, 128, 2529-2539.                                     | 4.1 | 7         |
| 53 | Laparoscopic Partial Splenectomy for Unknown Primary Cancer: A Stepwise Approach. <i>Annals of Surgical Oncology</i> , 2017, 24, 1134-1134.   | 1.5 | 6         |
| 54 | Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. <i>Oncology</i> , 2020, 98, 836-846. | 1.9 | 6         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Challenges of Efficacy Assessments in Pseudomyxoma Peritonea. <i>Oncologist</i> , 2015, 20, e3-4.  | 3.7 | 3         |
| 56 | FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6. | 2.3 | 3         |
| 57 | Cancer of Unknown Primary Presenting as Boneâ€Predominant or Lymph Nodeâ€Only Disease: A Clinicopathologic Portrait. <i>Oncologist</i> , 2021, 26, e650-e657.  | 3.7 | 3         |
| 58 | Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1270.                             | 2.5 | 3         |
| 59 | Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 48-56.e2.                                | 2.3 | 2         |
| 60 | Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.        | 1.4 | 2         |
| 61 | Favorable Subsets Among Cancers of Unknown Primary. , 2016, , 151-172.   |     | 1         |
| 62 | Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2268-2274.                                     | 1.4 | 0         |
| 63 | How quality of life can inform management decisions in later-line metastatic colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 22, 1-16.                        | 0.3 | 0         |
| 64 | Quality-of-life concerns in patients with metastatic colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 22, 2-6.   | 0.3 | 0         |
| 65 | How quality of life can inform management decisions in later-line metastatic colorectal cancer: Q&A.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 22, 13-14.                  | 0.3 | 0         |